If you talk about the most popular thing recently, “Qianjintiansu” is on the list. Recently, many listed pharmaceutical companies have fluctuated greatly in their stock prices due to the concept of Qianjintiansu.
According to preliminary statistics, as of now, more than ten listed companies have made clarifications on the situation of fenugreek on the investor interaction platform. In addition, many listed pharmaceutical companies have abnormal stock fluctuations due to concept speculation. Industry insiders advise,It is still far from the listing of fenugreek as a drug, and investors need to pay attention to the risks。
traditional Chinese medicineClass listed companies rose when they were “in touch”, and now this “fire” is still burningtraditional Chinese medicinematerial market.
traditional Chinese medicineThe price of vines soared
According to Zhongxin Finance and Economics, “The price of Qianjintan has changed rapidly in recent days.” On the 17th, a relevant person in charge of a medicinal material sales company in Bozhou, Anhui told reporters.
“On the 13th and 14th, the fire hadn’t started yet,The highest retail price of Qianjin rattan is 60 yuan per kilogram, and there are also 20 to 30 yuan per kilogram.. “The person in charge said,”Today (17th) large goods (from 100 kg) have been sold for 110 yuan per kilogram, and the retail price has reached 160 yuan per kilogram。”
According to the person in charge, recently, many old customers are also asking about vines. Some people want to buy them for home cooking, and there are pharmaceutical factories to extract them. Some clinics and hospitals are also asking for vines.
Taking into account the demand for this period of time, the person in charge predicted that the price may continue to rise in the future.
According to Red Star News, the real fire in the Chinese herbal medicine industry is the slices of Qianjin rattan. However, because the vine of honeysuckle is also called Qianjin vine, the Chinese herbal medicine market is mixed with mermaids, and the vine of honeysuckle is used as the vine for sale.
According to relevant Chinese herbal medicine websites, there are suppliers from Guangdong whose price was 43 yuan/kg before, and there are also suppliers from Jiangxi whose price was 48 yuan/kg.
“One price per day, now the lowest price of Qianjin rattan is 160 yuan/kg. “A Chinese herbal medicine wholesaler from Anhui told the Red Star Capital Bureau.
The wholesaler told reporters,Qianjinvine was only over 40 kilograms the day before yesterday, but prices started skyrocketing yesterday. “Yesterday, a customer bought a ton, and our quotation was 93 yuan/kg.”
It is reported that there have been a number of pieces of information about the acquisition of Qianjinteng on some social media recently. Many people said, “A large number of acquisitions can be delivered to your door.”
Growers: Maointerest rateup to 60%
There are still tens of thousands of orders not dispatched
Wholesalers of Chinese herbal medicines have already made a lot of money, and growers have also begun to sell seedlings and expand their production.
According to Red Star News, “This seedling is too hot. Hurry up and order it. It may be gone in two days.” A grower who sells seedlings said that the price of large quantities of seedlings can be as low as 2 yuan per root.
The grower said,Although the unit price is only about 2 yuan, the gross profit is 1.2 yuan, plus all the labor courier costs, the gross profit is 1.2 yuan.interest ratecan reach 60%。
Before the fire of Qianjinvine seedlings, the wholesale price was only about 1 yuan. The Red Star Capital Bureau has searched multiple e-commerce platforms. At present, the unit price of Qianjin rattan seedlings is roughly around 10 yuan per root.
According to the above-mentioned growers,At present, there are still tens of thousands of orders that have not been issued, and there are still several thousand in hand. By next month, the scale will be expanded to 100,000.。
In addition, some growers said that they would continue to expand production. Due to the fire, they were not prepared to reduce the unit price of about 10 yuan.
The reporter learned that most of the planters’ seedlings of the vines are bred from seeds, which are mainly root growth and reproduction.
What is fenugreek？
What does it mean to be granted an invention patent?
According to the official WeChat account of Beijing University of Chemical Technology, on May 10, a new drug for the treatment of COVID-19 discovered by Chinese scientists was granted a national invention patent. The patent specification shows,10uM (micromol/L) of fenugreek inhibits the replication of coronavirus by 15393 times。
Image source: Screenshot of the official WeChat account of Beijing University of Chemical Technology
According to the State Intellectual Property Office, the patent name is “Pangolin coronavirus xCoV and its application and application of drugs against coronavirus infection”,The so-called fenugreek can inhibit the virus in vitro, and it is a pangolin coronavirus that is very similar to the new coronavirus in the expression of S protein.。
“The pangolin coronavirus xCoV has 92.5% homology to the S protein of SARSCOV2. The receptors of xCoV infected cells are the same as those of SARSCOV2, both of which are angiotensin-converting enzyme 2 (ACE2). However, xCoV does not infect humans and can be used for Screening of active drugs and vaccines of SARSCOV2 virus, and can also be used to prepare attenuated vaccines or inactivated vaccines against SARSCOV2 virus.” The patent specification states.
According to public information, the main efficacy and role of Radix chinensis as a Chinese herbal medicine is to clear away heat and detoxify.According to the official website of the Food and Drug Administration, there are currentlyYunnan BaiyaogroupDali Pharmaceuticallimited liability company,Yunnan BaiyaoThe four companies of the group, Wenshan Qihua Co., Ltd., Shenyang Guancheng Pharmaceutical Co., Ltd., and Yunnan Bio Valley Pharmaceutical Co., Ltd., have production batch numbers of Qianjintansu tablets.
In this regard, Tong Yigang, the inventor of related patents related to jintensu, mentioned that at present, the four companies with production batch numbers only have batch numbers, but they have not produced it, and the drug cannot be bought in China. After this report attracted attention, some companies were more interested in this, and some of the four companies with batch numbers also found Tong Yigang.
What does it mean to be granted an invention patent? According to Sino-Singapore Jingwei, an intellectual property practitioner said that the drug patent is more similar to a defensive patent, but it needs to be further determined based on patent search and analysis. “You can apply for a patent if you invent a new drug (new molecular formula), a new way of using the drug, or a process that can produce the same effect with less cost or less time.. ‘ said the practitioner.
According to public information, in patent applications in the fields of chemistry and biomedicine, the evaluation of creativity in my country needs to be proved by comparing experimental data. According to the provisions of Chapter 10 of Part II of the Guidelines for Patent Examination, the invention of known product use requires that the new use cannot be obvious from the structure, composition, molecular weight, known physical and chemical properties of the product itself and the existing use of the product. It is creative if it is derived or foreseen, but takes advantage of the newly discovered nature of the product and produces unexpected technical effects.
Therefore, in terms of being able to obtain national invention patents,Or it means that the inhibition of the virus by fenugreek in vitro has been confirmed。
As far as patents are concerned, Professor Tong Yigang from the School of Life Science and Technology of Beijing University of Chemical Technology said in a live broadcast on the 16th,The current PCT (Patent Cooperation Treaty, an international cooperation treaty in the field of patents) for the patent has expired. The above-mentioned intellectual property practitioner explained, “The impact of the expiration of the PCT is that, taking the United States as an example, if the PCT expires, the US examiner retrieves the patent published in China in May, and will reject the patent as prior art in the United States. The patent applied for.” In response, Tong Yigang said that the team is currently re-submitting the PCT application.
Expert: At present, it is said that fenugreek is expected to be used to treat the new crown
still far away
According to Jiemian News, similar to some “anti-coronavirus” drugs that have previously attracted public attention,Tong Yigang’s team has only done in vitro experiments on phyllostachys at the cellular level.。
Zhang Hongtao, a former research associate professor at the University of Pennsylvania School of Medicine, told Jiemian News that the data of “inhibiting virus replication by 15,393 times” is not that important to some extent.Because in vitro, for example, the use of alcohol can also reduce the virus tens of thousands of times。
The most important thing is to go back to the human trials to see if fenugreek can achieve such an inhibitory effect in human trials. “It’s like you can kill all the virus with 70% alcohol, but you can’t make the blood alcohol concentration reach 70% after drinking.Without this level, there is no way to achieve the effect of this drug. Zhang Hongtao said. This is what is commonly referred to as “blood drug concentration” in the development of new drugs. If the required blood drug concentration cannot be achieved on the premise of ensuring safety, it will not be effective.
In fact, only as a “promising drug candidate”,At present, it is said that fenugreek is expected to be used to treat the new crown, but it is still far away。
It is well known that new drug development needs to go through three stages of drug discovery, preclinical research and clinical research including multi-phase trials to confirm or discover the clinical, pharmacological, pharmacodynamic effects, adverse reactions, and Absorption, distribution, metabolism and excretion characteristics to determine the safety and efficacy of the investigational drug.
Data show that in the development of new drugs, the median duration of clinical trials in the field of infection is 7.1 years, and the success rate of new drug development is only 19.10%.The preclinical in vitro results are excellent, but there are countless candidate drugs that have failed in human clinical trials.From this point of view, there is nothing special about Qianjintiansu.
Zhang Hongtao further stated that even if there are some preliminary data from animal experiments, it may be easier to judge the effect of fenugreek in humans. As far as the current research progress is concerned, there are still many unknown factors, and there is still a long way to go before the real drug and approval for marketing. In addition, he also pointed out that there may be a hype about fenugreek at the moment,For example, it is “jumpy and infeasible” to directly buy plants containing fenugreek to prevent the new crown.。
Unusual fluctuations in related concept stocks
A number of listed companies are in an emergencyannouncement
Taking this concept, on May 16, Bio Valley,Unionway、Dali Pharmaceutical、Step Pharma、North China Pharmaceutical、Qianjin PharmaceuticalWhen the company’s stocks are on a daily limit, Bio Valley is far ahead with two “30cm”.
On the morning of May 17, “Daily Economic News” called the sales and service department of Bio Valley, and the operator said that the company does not currently sell fenugreek related products. Received notification about the start of production.
It is worth noting that since the evening of May 16th, there have beenNorth China Pharmaceutical、Qianjin PharmaceuticalIn the announcement, the above-mentioned companies also made relevant clarifications. The announcement shows,A number of listed pharmaceutical companies that have been “hyped” by the market actually do not have fenugreek related business。
North China PharmaceuticalThe announcement of abnormal fluctuations in stock trading shows that the deviation of the daily closing price increase of the company’s stock for 3 consecutive trading days on May 12, May 13, and May 16, 2022 exceeded 20%.securitiesThe relevant provisions of the Exchange Trading Rules are abnormal fluctuations in stock trading. The company also stated that recently, the company noticed that some media reports mentioned that “North China Pharmaceutical and the expert team have technical cooperation related to phyllostachys”. After verification by the company, at present,The company has not carried out technical cooperation with related expert teams, and the company has no related products.。
also,Qianjin PharmaceuticalbecausesecuritiesThe abbreviation with “Qianjin” was also blindly hyped, and it closed at the daily limit on May 16. On the evening of the 16th, Qianjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading, and clarified in the announcement that,The company does not have the production and sales of fenugreek。
Qianjin Pharmaceutical’s announcement shows that the main component of the company’s main product, Fuke Qianjin Tablets, is the alkaloid extracted from dried cane; benzyl isoquinoline alkaloids. The two are not the same substance, but have great differences in chemical structure and pharmacological effects.
Step PharmaIt also stated in the announcement of abnormal stock fluctuations released on the evening of May 16 that it has recently noticed that there are media reports that the company has been listed as a concept stock of Qianjintansu. After verification, the company’s wholly-owned subsidiary Shandong Danhong Pharmaceutical Co., Ltd. (formerly Heze)Step PharmaCo., Ltd.) has “a kind of preparation method of fenugreek hydrochloride[专利号：ZL201010556531.0]”The invention patent,However, the company currently has no research and development, production and sales of fenugreek related products.。
Bio Valley stated in the announcement of abnormal stock fluctuations released on May 17 that the company has the equipment and technical conditions for the production of Qianjintansu tablets, and obtained the re-registration of the drug on April 28, 2020, and the drug approval number is valid until 2025.Since the product has not been produced and sold in the past two years, when the production is resumed, an application for on-site inspection must be submitted to the Yunnan Provincial Drug Administration, and the market can only be sold after passing the on-site review by the Yunnan Provincial Drug Administration.. The announcement also shows that within the last two trading days with transactions (May 13, 2022, May 16, 2022), the deviation of the company’s stock closing price increase has accumulated to 63.14%.
According to the Economic Information Daily, industry insiders reminded that Qianjintiansu has just gone through the drug discovery stage, and subsequent successful listing requires a long process and many uncertain factors. At present, the market is mainly hyping the concept of related stocks. Investors should pay attention to the risks and avoid blindly following the trend.
On May 18, the share prices of “Qianjin Veng concept stocks” fell one after another, among which Bio Valley’s share price fell 16.69% to close at 11.08 yuan; North China Pharmaceutical’s share price fell by the limit to close at 7.44 yuan; Buchang Pharmaceutical’s share price fell 8% to close at 21.17 yuan .
According to The Paper, thousands ofTong Yigang, the inventor of the related patents related to jintensu, said that the fluctuation of the secondary market has nothing to do with it.。
per commenter：
Stay away from the nonsensical hype of the concept of fenugreek
In this regard, every commentator Xu Shuai commented: A concept, chicken and dog rises to the sky, this time the capital marketthemeThe protagonist’s turn is Qianjin Fujisu.
For a time, the A-share Qianjintansu was hyped one after another. The funny thing is that Qianjin Pharmaceutical sells gynecological medicines, but because of the “qianjin” in its name, it is also sought after by funds.
There is a causal relationship between the two news of fenugreek, that is, the demand for fenugreek has exploded, and the increase in seedling prices confirms this demand. But in fact, the industrialization of Qianjintiansu is expected to be far away.
The first is that the published data on fenugreek is the result of in vitro experiments,In vitro testing and in vivo testing are two different things. Besides,From laboratory data to approval for marketing, it has to go through patented drugs, animal experiments and clinical trials. Each process faces a long cycle and force majeure. Without going through these processes, a new drug is not considered a complete commercialization process.
Secondly, although there are market supply and demand reasons for the increase in the price of vine seedlings, there are many types of such reasons, such as the mismatch between supply and demand due to seasons. In the past two years, the price of Chinese herbal medicines has been in a price increase cycle, and the price of vine seedlings may also increase due to this reason.Linking the price increase of vine seedlings to the new crown is actually a misattribution。
FromDali PharmaceuticalBio Valley, Qianjin Pharmaceutical, these hotly-hyped concept stocks, some do not have fenugreek at all, some have not been produced, and it is far from the time for large-scale use of fenugreek to treat the new crown.
What’s more, there are some hot stocks that have been subject to regulatory attention due to capital occupation and other issues. For example, the cumulative increase of Bio Valley in the past three trading days is as high as 74.31%, just because it claims that it has the conditions to produce the new crown treatment drug Qianjinsu.The author noticed that at the beginning of May, Bio Valley was heldshareholderJinshajiang was inquired about the illegal occupation of funds by the Beijing Stock Exchange, and Jinshajiang also received regulatory measures taken by the Yunnan Provincial Securities Regulatory Bureau to make corrections. Although the company has given people unlimited space for imagination, these are pale in the face of the lack of internal control. Only when listed companies have the foundation of corporate governance can they talk about development. This is common sense.
But it doesn’t matter whether you have these common senses, as long as your obsession is deep enough and your emotions are high enough, the nonsensical hype of “say you have it, you have it” will continue. But historical experience has proved that nonsensical hype is like a gust of wind, which comes quickly and leaves quickly. Remdesivir was first regarded as a treatment for the new crown, and it also caused a lot of hype that year. But looking at the stock price of the concept stocks after two years, which concept stock has not returned to its original place?
Fortunately, in the era of registration system with information disclosure as the core, listed companies pay more and more attention to the information disclosure of hot events. In the past two days, a number of listed companies have refuted the rumors about Qianjintansu, which will help to reverse the craziness of crazy speculation in time. These listed companies have set an example, and it is hoped that more listed companies can also disclose real information on a compliant information disclosure platform.
In addition, regulators should also pay attention to verifying whether there are multiple account manipulations, “grabbing hats” and other violations in the speculation. We should focus on whether there are capital manipulators who use self-media to spread rumors and use capital advantages to raise stock prices for profit.
(Article source: Daily Economic News)
